{
    "nctId": "NCT04805736",
    "briefTitle": "Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer",
    "officialTitle": "A Pilot Study of Single-Dose Camrelizumab and/or Microwave Ablation in Women With Early-Stage Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Safety of Microwave Ablation Combined With Camrelizumab",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female.\n2. Age 20-65 years.\n3. Invasive carcinoma confirmed by core biopsy.\n4. Newly diagnosed breast cancer patients, without adjuvant therapy.\n5. Imaging findings showed a single breast tumor with a maximum diameter of 3 cm, no distant metastasis, and no invasion of the skin and chest wall.\n6. Systematic ultrasound is able to visualize lesions.\n7. Surgical treatment was planned.\n8. The functional level of major organs must meet the following requirements:\n\n   1. blood routine: neutrophil (ANC) \u2265 1.5 \u00d7 109/L; platelet count (PLT) \u2265 90 \u00d7 109/L; hemoglobin (Hb) \u2265 90 g/L;\n   2. blood biochemistry: total bilirubin (TBIL) \u2264 upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 1.5 \u00d7 ULN; alkaline phosphatase \u2264 2.5 \u00d7 ULN; blood urea nitrogen (BUN) and creatinine (Cr) \u2264 1.5 \u00d7 ULN;\n   3. coagulation: international normalized ratio (INR) or prothrombin time (PT) \u2264 1.5 \u00d7 ULN; activated partial thromboplastin time (APTT) \u2264 1.5 \u00d7 ULN.\n   4. Heart: left ventricular ejection fraction (LVEF) \u2265 50% as assessed by echocardiography (ECHO) or multigated acquisition (MUGA).\n   5. Thyroid function: thyroid stimulating hormone (TSH) \u2264 ULN; if abnormal, T3 and T4 levels should be investigated, and normal T3 and T4 levels can be included.\n   6. Urinalysis: urine protein \\< 2 +, if urine protein \u2265 2 +, 24-hour urine protein quantification must show protein \u2264 1 g.\n9. Voluntarily participate in this study, sign informed consent, have good compliance and are willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Tumor involving skin, ulceration, inflammatory breast cancer patients\n2. Fatty breast cancer.\n3. Tumors on the deep surface of areolar region\n4. KPS score \\< 70, or ECOG score \\> 2\n5. Patients with a history of concomitant collagen connective tissue disease, or any active autoimmune disease or autoimmune disease.\n6. Prior radiotherapy or prior use of investigational drugs or other immunosuppressive agents\n7. Heart, brain, lung, kidney and other vital organ failure, liver and kidney dysfunction;\n8. Uncorrectable severe coagulopathy\n9. Patient is pregnant or lactating\n10. Poor glycemic control in diabetes\n11. Patients with foreign body implantation around the tumor\n12. Patients with severe scars on the skin of the treatment area (protruding from the skin surface, width \u2265 1 cm)\n13. History of chronic immunosuppression, prior immunotherapy, recent vaccination (\\< 4 weeks)\n14. Human immunodeficiency virus (HIV) infection, active hepatitis B (hepatitis B indicates antigen positive and HBV DNA \u2265 500 IU/ml), hepatitis C (hepatitis C antibody positive and HCV-RNA above the lower limit of detection of the analytical method).\n15. Concurrent medical conditions that, in the judgment of the investigator, would jeopardize the subject's safety, could confound the study results, or affect the subject's completion of this study.",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}